

ForPatients

by Roche

Non Hodgkin Lymphoma (NHL) Follicular Lymphoma Diffuse Large B-Cell Lymphoma (DLBCL)

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Status
Completed

Trial Runs In
3 Countries

Trial Identifier
NCT02611323 2015-001998-40
GO29833

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and venetoclax in participants with relapsed or refractory FL, and with rituximab, polatuzumab vedotin, and venetoclax in participants with DLBCL. Participants with FL who achieve complete response (CR), partial response (PR), or stable disease (SD) at the end of induction therapy will receive post-induction treatment with obinutuzumab and venetoclax, and participants with DLBCL who achieve CR or PR at the end of induction (EOI) will receive post-induction treatment with rituximab and venetoclax.

Hoffmann-La Roche
Sponsor

Phase 1/Phase 2
Phase

NCT02611323 2015-001998-40 GO29833
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No
